Kun for helsepersonell

Søk 

Menu

Close

LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss
OmAlopecia AreataLITFULO virkningsmekanismeSALT EvalueringEffektALLEGRO-2b/3 studieoversiktHårrespons i hodebunnenPasientrapporterte utfallØyenbryn og vipperesponsFør og etter bilderSikkerhetALLEGRO-2b/3 bivirkningerSamlede sikkerhetsdataYtterligere sikkerhetsinformasjonKom i gangDoseringScreening og oppfølgingSette pasientmålPasientprofilerOpplæringsmateriellMateriellVideo
Øyenbryn- og øyenvipperesponsEyebrow and eyelash responses in pivotal study1Proportions of patients with EBA or ELA responses at Weeks 24 and 482,3*

Eyebrow Response

Eyelash Response

Tab Number 3

Tab Number 4

Tab Number 5

LITFULO helped more patients achieve moderate-to-normal eyebrows vs placebo at Week 24, and continued through Week 481,2,4

Percentages are based on the number of participants who had abnormal scores at baseline.  Response is based on at least a 2-grade improvement from baseline or a normal score on the 4-point scale among the participants with an abnormal score at baseline. The EBA scale includes scores of 0 (none), 1 (minimal), 2 (moderate), and 3 (normal).

Eyebrow Assessment Scale1,4

0 = None Eyebrow

  • No eyebrow hair


1 = Minimal Eyebrow

  • Normal or decreased density of one or both eyebrows with large gap(s)
  • Severely decreased density of one or both eyebrows with or without gap(s)


2 = Moderate Eyebrow

  • Normal density of both eyebrows with short gap(s) that does not significantly distort the appearance of the eyebrows, OR
  • Mildly decreased density of eyebrows with or without short gap(s), OR
  • Moderately decreased density of eyebrows without short gap(s)
  • There is visual definition of eyebrows at a distance of 3 feet


3 = Normal Eyebrow 

  • Normal density of both right and left eyebrows spanning usual length (ie, from glabella to near temple) and width. There are no gap(s)


Patients with EBA scores of 0-2 were included in the EBA assessments throughout the study.



The EBA and ELA scores were rated by the investigators. The EBA and ELA were both validated for reliability, validity, and ability to detect differences before implementation in the pivotal trial. Administration to trial participants was standardised to ensure consistent assessments. Assessments in several additional data sources were performed which confirmed the strong measurement properties of both measures.3

Limitations and biases


  • Participants with missing EBA/ELA data at a visit due to COVID-related reasons are excluded in the analyses at that visit4
  • Participants with EBA/ELA missing data at a visit due to reasons unrelated to COVID-19 are considered as nonresponders for that visit4
  • Percentages are calculated based on the number of participants who had abnormal scores at baseline1,2

Eyebrow responses were prespecified secondary endpoints not controlled for multiplicity. The results should be interpreted with caution and could represent chance findings.2

Note: There was no placebo after Week 24. These results do not reflect the patients who switched from placebo to LITFULO 50 mg treatment after Week 24.1

Participants with missing EBA/ELA data at a visit due to COVID-related reasons were excluded from the analysis at that visit; those with missing data due to reasons unrelated to COVID-19 were considered nonresponders for that visit.4

The EBA/ELA are clinician-reported measures that characterise eyebrow/eyelash hair loss on a 4-point ordinal scale.2,4

Inclusion in the study was not based on eyebrow or eyelash involvement. Of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 82% and 82% had abnormal eyebrows at baseline, respectively. And of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 73% and 74% had abnormal eyelashes at baseline, respectively.
See real results in real patients Før og etter bilderLoading
EBA=eyebrow assessment; ELA=eyelash assessment.
References:1. LITFULO (ritlecitinib) Summary of Product Characteristics. 2. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 3. Data on file. Pfizer Inc; New York, NY. 4. King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2 
LITFULO helped more patients achieve moderate-to-normal eyelashes vs placebo at Week 24, and continued through Week 481,2,4

Percentages are based on the number of participants who had abnormal scores at baseline.  Response is based on at least a 2-grade improvement from baseline or a normal score on the 4-point scale among the participants with an abnormal score at baseline. The ELA scale includes scores of 0 (none), 1 (minimal), 2 (moderate), and 3 (normal).

Eyelash Assessment Scale1,4 0 = None Eyelash
  • No eyelashes of both right and left upper and lower eyelashes

1 = Minimal Eyelash
  • Modestly or severely decreased density of and/or large gap(s) in one or both upper eyelashes

2 = Moderate Eyelash
  • Normal density of both upper eyelashes without gap(s), and decreased density or gap(s) is present in one or both lower eyelashes, OR 
  • Normal density of both upper eyelashes with short gap(s), OR
  • Mildly decreased density of one or both upper eyelashes with or without short gap(s) 

3 = Normal Eyelash 
  • Normal density of both right and left upper and lower eyelashes from near medial canthus to near lateral canthus without any gap(s) 

Patients with ELA scores of 0-2 were included in the ELA assessments throughout the study.

The EBA and ELA scores were rated by the investigators. The EBA and ELA were both validated for reliability, validity, and ability to detect differences before implementation in the pivotal trial. Administration to trial participants was standardised to ensure consistent assessments. Assessments in several additional data sources were performed which confirmed the strong measurement properties of both measures.3

Limitations and biases:
  • Participants with missing EBA/ELA data at a visit due to COVID-related reasons are excluded in the analyses at that visit4
  • Participants with EBA/ELA missing data at a visit due to reasons unrelated to COVID-19 are considered as nonresponders for that visit4
  • Percentages are calculated based on the number of participants who had abnormal scores at baseline1,2

Eyebrow responses were prespecified secondary endpoints not controlled for multiplicity. The results should be interpreted with caution and could represent chance findings.2

Note: There was no placebo after Week 24. These results do not reflect the patients who switched from placebo to LITFULO 50 mg treatment after Week 24.1

Participants with missing EBA/ELA data at a visit due to COVID-related reasons were excluded from the analysis at that visit; those with missing data due to reasons unrelated to COVID-19 were considered nonresponders for that visit.4

The EBA/ELA are clinician-reported measures that characterise eyebrow/eyelash hair loss on a 4-point ordinal scale.2,4

Inclusion in the study was not based on eyebrow or eyelash involvement. Of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 82% and 82% had abnormal eyebrows at baseline, respectively. And of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 73% and 74% had abnormal eyelashes at baseline, respectively.
See real results in real patients Før og etter bilderLoadingEBA=eyebrow assessment; ELA=eyelash assessment.
References:1. LITFULO (ritlecitinib) Summary of Product Characteristics. 2. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 3. Data on file. Pfizer Inc; New York, NY. 4. King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2

tab 6

Explore safety data SikkerhetLoading
Get appropriate patients started on LITFULO today Kom i gang Loading
PP-LGF-NOR-0026 | Utarbeidet 04.2025

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 

Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1 (lege, tannlege, offentlig godkjent sykepleier, farmasøyt, optiker, tannpleier, samt studenter i disse fag)

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei